Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 13/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17663684 | 0.87 | BTK (0.42) | PRMT5WDR77BTKAR | |
| SCHEMBL17660264 | 0.82 | BTK (0.36) | BTKCDK4CDK6 | |
| SCHEMBL17664672 | 0.80 | BTK (0.39) | BTK | |
| SCHEMBL21207713 | 0.80 | BTK (0.35) | BTK | |
| SCHEMBL17645911 | 0.76 | BTK (0.43) | PRMT5WDR77BTK | |
| SCHEMBL17645688 | 0.76 | BTK (0.43) | PRMT5WDR77BTK | |
| SCHEMBL17645947 | 0.74 | BTK (0.45) | BTK | |
| SCHEMBL17645880 | 0.73 | BTK (0.41) | PRMT5WDR77BTK | |
| SCHEMBL17645887 | 0.73 | BTK (0.55) | BTK | |
| SCHEMBL17645704 | 0.72 | BTK (0.46) | PRMT5WDR77BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253023-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LYN | PRMT5 2178/4885WDR77 2056/4885BTK 1/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | PRMT5 2913/4885WDR77 1817/4885BTK 1/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | PRMT5 2178/4885WDR77 2056/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.